Zymeworks
- Market cap
- 1.90B
- P/E (TTM)i
- -13.13
- P/Bi
- 23.69
- EPSi
- -1.08
- Div yieldi
- 0.00%
- 52W posi
- 69%
Anonymous reader poll. Unscientific, not investment advice.
About Zymeworks
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
- Founded
- 2003
- CEO
- Mr. Kenneth Galbraith
- Employees
- 264
- Headquarters
- Middletown, Delaware, United States of America
- Fiscal year end
- 12-31
- Website
- zymeworks.com
Company profile
- Exchange
- US
- Symbol
- ZYME
- Market-cap rank
- #2828
- Listing date
- 2017-04-28
- Market cap
- 1.90B
- Float cap
- 1.77B
- Shares out
- 71.75M
- Float shares
- 66.63M
Sectors & themes
Quote time 2026-10-08 05:35:07 · For reference only, not investment advice and not tailored to your situation.